The Canadian Cancer Survivor Network (CCSN) is doing a Call out for our Patient & Caregiver Questionnaire on Lung Cancer – Lumakras . The survey will remain open until September 5, 2022.
The purpose of this survey is to provide the Canadian Cancer Survivor Network with insights and perspectives about living with and managing a lung cancer diagnosis from patients and caregivers in order to complete a patient evidence submission for Lumakras (sotorasib). The indication is for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
The survey will remain open until September 5, 2022.
The pan-Canadian Oncology Drug Review invites patient groups to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
Thank you for your participation!